Wells Fargo analyst Tiago Fauth raised the firm’s price target on Wave Life Sciences to $22 from $11 and keeps an Overweight rating on the shares. The change reflects data de-risking key programs and greater pipeline/technology value to reflect positive updates across different therapeutic modalities, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target raised to $17 from $13 at JPMorgan
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302
- Raymond James upgrades Wave Life to Strong Buy on ‘historic’ milestone
- Wave Life Sciences upgraded to Strong Buy from Outperform at Raymond James